https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/gene-therapy-trial-patients-fanconi-anaemia-open-gosh/
Gene therapy trial for patients with Fanconi anaemia to open at GOSH
22 Mar 2016, 5:24 p.m.
A clinical trial is to open at Great Ormond Street Hospital (GOSH) that will test the use of gene therapy during transplantation for the treatment of young people with Fanconi anaemia. The trial will be led by Dr Claire Booth, Dr Phil Ancliff and Professor Adrian Thrasher – who is the Gene, stem and cellular therapies Theme Lead at the Great Ormond Street BRC.
Fanconi anaemia is a life-limiting, inherited haematological disorder which causes bone marrow failure in childhood as well as other serious complications. Children can be treated with a bone marrow transplant but the success of this procedure depends on finding a well matched donor for the patient.
The clinical trial due to open at GOSH in the coming months will assess whether gene therapy could offer hope to children lacking a suitable donor for transplant.
Researchers will make use of the BRC-funded GMP facility to genetically modify the patient’s own stem cells during the trial.
Study sheds light on sight-threatening arthritis in children
A team from UCL GOSH and Moorfields Eye Hospital, have discovered B-cells alongside T-cells, play a major role in the development of arthritis‑associated eye disease, JIA‑uveitis.
Lab-grown mini-stomachs could boost understanding of rare diseases
Researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have developed the first-ever lab-grown mini-stomach that contains the key components of the full-sized human organ.
When it is OK to link our data?
A guide for researchers by children and young people containing key principles which reflect children’s and young people’s views about when it is ok to link their data for research.
NIHR launches £13.7m investment into brain tumour research
The National Institute for Health and Care Research (NIHR) has announced a £13.7 million investment that will support ground-breaking research to develop novel brain tumour treatments in the UK.